This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 3 & 6 clinical data
XOVOLTIB® significantly improved PFS in patients with stable brain metastases at time of enrolment and common mutations versus chemotherapy1

LUX-Lung 3 and 6: combined PFS analysis in patients with brain metastases 

  • Significant PFS in patients with stable brain metastases at the time of enrolment and common mutations versus chemotherapy (HR=0.50; P=0.0297)1
  • XOVOLTIB® significantly improved tumour response rates in patients with and without brain metastases and common EGFR mutations versus chemotherapy1
  • Median time to CNS progression was longer with XOVOLTIB® versus with chemotherapy (LUX-Lung 3: 15.2 months [95% CI: 7.7–29.0] and 5.7 months [95% CI: 2.6–8.2]; LUX-Lung 6: 15.2 months [95% CI: 3.8–23.7] and 7.3 months [95% CI: 3.7–10.9])1

EGFR= epidermal growth factor receptor; PFS= progression-free survival; HR=hazard ratio; CI=confidence interval

You may be interested in: 

EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer

Is this information compelling to you?

References

  1. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.
  1. [1] Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. [2] Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. [3] Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. [4] Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. [5] Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. [6] Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. [7] Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. [8] Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. [9] Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. [10] Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. [11] Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277

  12. [12] XOVOLTIB® Local pack insert version dated 21st July 2017

In case you come across any adverse events related to our products, please report it to PV team immediately.
Phone: +91 9819241697
Email: PV_local_India@boehringer-ingelheim.com

For any query on Boehringer Ingelheim India's product or therapy area, kindly contact
Phone: 1800227887
Email: medical.query.mum@boehringer-ingelheim.com

Back to top